1. Home
  2. CGON vs ZD Comparison

CGON vs ZD Comparison

Compare CGON & ZD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • ZD
  • Stock Information
  • Founded
  • CGON 2010
  • ZD 1995
  • Country
  • CGON United States
  • ZD United States
  • Employees
  • CGON N/A
  • ZD N/A
  • Industry
  • CGON
  • ZD Advertising
  • Sector
  • CGON
  • ZD Consumer Discretionary
  • Exchange
  • CGON NYSE
  • ZD Nasdaq
  • Market Cap
  • CGON 1.3B
  • ZD 1.4B
  • IPO Year
  • CGON 2024
  • ZD 1999
  • Fundamental
  • Price
  • CGON $25.62
  • ZD $32.44
  • Analyst Decision
  • CGON Strong Buy
  • ZD Hold
  • Analyst Count
  • CGON 10
  • ZD 6
  • Target Price
  • CGON $64.00
  • ZD $49.67
  • AVG Volume (30 Days)
  • CGON 1.4M
  • ZD 569.2K
  • Earning Date
  • CGON 05-13-2025
  • ZD 05-08-2025
  • Dividend Yield
  • CGON N/A
  • ZD N/A
  • EPS Growth
  • CGON N/A
  • ZD 36.58
  • EPS
  • CGON N/A
  • ZD 1.76
  • Revenue
  • CGON $662,000.00
  • ZD $1,415,839,000.00
  • Revenue This Year
  • CGON N/A
  • ZD $7.37
  • Revenue Next Year
  • CGON $12,387.03
  • ZD $3.52
  • P/E Ratio
  • CGON N/A
  • ZD $18.48
  • Revenue Growth
  • CGON 224.51
  • ZD 3.24
  • 52 Week Low
  • CGON $14.80
  • ZD $29.15
  • 52 Week High
  • CGON $40.47
  • ZD $60.62
  • Technical
  • Relative Strength Index (RSI)
  • CGON 53.27
  • ZD 49.81
  • Support Level
  • CGON $24.79
  • ZD $31.38
  • Resistance Level
  • CGON $26.60
  • ZD $32.40
  • Average True Range (ATR)
  • CGON 1.39
  • ZD 1.13
  • MACD
  • CGON -0.01
  • ZD 0.16
  • Stochastic Oscillator
  • CGON 48.52
  • ZD 51.11

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About ZD Ziff Davis Inc.

Ziff Davis Inc is a focused digital media and internet company whose portfolio includes brands in technology, entertainment, shopping, health, cybersecurity, and martech. It has two reportable segments: Digital Media and Cybersecurity and Martech. The company's brands include Mashable, Ookla, Offers.com, IGN, and VPN among others. The majority of revenue is generated from Digital Media.

Share on Social Networks: